Ultivue Announces $50M Financing Round
Ultivue , a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping , today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005387/en/
This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.
Anna Yaeger, President and Portfolio Manager commented, "Ally Bridge Group is excited to be long term partners with Ultivue. We believe the company's differentiated kit-based approach to multiplex immunofluorescence is well positioned to capitalize on the spatial biology revolution and creates maximum flexibility to support academic, biopharma, and CRO customers."
“What Ultivue has is remarkably capable. They provide fast, accurate, previously unattainable multiplexed protein marker information at high resolution and on existing hardware. It is going to be exciting to see a well-resourced, well led Ultivue offer great capabilities to the biotech and pharma oncology community,” said Keith Crandell, Co-founder & Managing Director from ARCH Ventures.
“Ultivue is driving to make immunotherapy a reality for every patient that needs it with leading technology that enables advanced exploration and interrogation of tissue samples for precision medicine research. We’re proud to continue supporting the Ultivue team,” said Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures.
“We’re excited to welcome our newest investors, and greatly appreciate the support from our existing investment partners,” says Jacques Corriveau, President and CEO of Ultivue. “This funding will allow us to expand our commercial efforts while also increasing the scope of our research and development in order to remain at the forefront of innovation and provide biological insights for our customers as they work to address the challenge of therapeutic response rates in patients using immunotherapy.”
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-TIGO4.8.2021 16:02:10 CEST | Press release
Tigo Energy Unveils Energy Intelligence Platform to Simplify Fleet Management
AVEX-ENTERTAINMENT4.8.2021 16:02:09 CEST | Press release
Avex Releases 100% Hemp Cloth T-shirt
Q44.8.2021 15:02:05 CEST | Press release
Q4 Launches Suite of ESG Communications Products
ENEDYM4.8.2021 14:02:11 CEST | Press release
Enedym, Inc. Announces Two New Appointments To Board of Directors
CA-YELLOW.AI4.8.2021 13:35:08 CEST | Press release
yellow.ai Raises $78.15M to Deliver Total Customer Experience Automation
CA-VELODYNE-LIDAR,-INC.4.8.2021 12:50:04 CEST | Press release
ANYbotics Boosts Autonomous Mobile Robots with Velodyne Lidar Sensors
FL-H.I.G.-CAPITAL4.8.2021 12:11:11 CEST | Press release
H.I.G. Capital Acquires Hotel in Basel, Switzerland
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom